Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells

Post time 2024-5-22 00:44:36

journal：Expert Opinion on Therapeutic Targets

Authors：Subarno Paul; Subhajit Chatterjee; Saptarshi Sinha; Somya Ranjan Dash; Rajalaxmi Pradhan; Biswajit Das; Kunal Goutam; Chanakya Nath Kundu

Published date：2023-10-3

DOI：10.1080/14728222.2023.2266572

PDF link：https://www.tandfonline.com/doi/pdf/10.1080/14728222.2023.2266572

Article link：http://dx.doi.org/10.1080/14728222.2023.2266572

Article Source：Informa UK Limited。

Remark：

Post time 2024-5-22 00:44:37

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Taylor&Francis] Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Taylor&Francis] Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Taylor&Francis] Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells